If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Anti-Human CD11A Therapeutic Antibody (Raptiva). Recombinant monoclonal antibody to Human CD11A. Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, WB and most other immunological methods.
Immunogen
n/a
Other Names
Efalizumab;raptiva;214745-43-4;hu1124;DB00095ITGAL;integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1;alpha polypeptide);CD11A;integrin alpha-L;LFA 1;LFA-1A;LFA-1 alpha;integrin gene promoter;CD11 antigen-like family member